158 related articles for article (PubMed ID: 29449427)
21. The PDE4 Inhibitor Tanimilast Restrains the Tissue-Damaging Properties of Human Neutrophils.
Schioppa T; Nguyen HO; Salvi V; Maugeri N; Facchinetti F; Villetti G; Civelli M; Gaudenzi C; Passari M; Sozio F; Barbazza I; Tamassia N; Cassatella MA; Del Prete A; Bosisio D; Tiberio L
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563373
[TBL] [Abstract][Full Text] [Related]
22. Biologic Drugs: A New Target Therapy in COPD?
Yousuf A; Brightling CE
COPD; 2018 Apr; 15(2):99-107. PubMed ID: 29683730
[TBL] [Abstract][Full Text] [Related]
23. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.
Planagumà A; Domènech T; Pont M; Calama E; García-González V; López R; Aulí M; López M; Fonquerna S; Ramos I; de Alba J; Nueda A; Prats N; Segarra V; Miralpeix M; Lehner MD
Pulm Pharmacol Ther; 2015 Oct; 34():37-45. PubMed ID: 26271598
[TBL] [Abstract][Full Text] [Related]
24. Evidence on the identity of the CXCR2 antagonist AZD-5069.
Norman P
Expert Opin Ther Pat; 2013 Jan; 23(1):113-7. PubMed ID: 22992174
[TBL] [Abstract][Full Text] [Related]
25. CXCR2 antagonists block the N-Ac-PGP-induced neutrophil influx in the airways of mice, but not the production of the chemokine CXCL1.
Braber S; Overbeek SA; Koelink PJ; Henricks PA; Zaman GJ; Garssen J; Kraneveld AD; Folkerts G
Eur J Pharmacol; 2011 Oct; 668(3):443-9. PubMed ID: 21458445
[TBL] [Abstract][Full Text] [Related]
26. Blockade of CXCR2 signalling: a potential therapeutic target for preventing neutrophil-mediated inflammatory diseases.
Boppana NB; Devarajan A; Gopal K; Barathan M; Bakar SA; Shankar EM; Ebrahim AS; Farooq SM
Exp Biol Med (Maywood); 2014 May; 239(5):509-18. PubMed ID: 24625439
[TBL] [Abstract][Full Text] [Related]
27. A novel flow cytometric assay of human whole blood neutrophil and monocyte CD11b levels: upregulation by chemokines is related to receptor expression, comparison with neutrophil shape change, and effects of a chemokine receptor (CXCR2) antagonist.
Nicholson GC; Tennant RC; Carpenter DC; Sarau HM; Kon OM; Barnes PJ; Salmon M; Vessey RS; Tal-Singer R; Hansel TT
Pulm Pharmacol Ther; 2007; 20(1):52-9. PubMed ID: 16406722
[TBL] [Abstract][Full Text] [Related]
28. The chemokine CXCR2 antagonist (AZD5069) preserves neutrophil-mediated host immunity in non-human primates.
Uddin M; Betts C; Robinson I; Malmgren A; Humfrey C
Haematologica; 2017 Feb; 102(2):e65-e68. PubMed ID: 27742769
[No Abstract] [Full Text] [Related]
29. Humoral immunity and delayed-type hypersensitivity in healthy subjects treated for 30 days with MK-7123, a selective CXCR2 antagonist.
Seiberling M; Kamtchoua T; Stryszak P; Ma X; Langdon RB; Khalilieh S
Int Immunopharmacol; 2013 Oct; 17(2):178-83. PubMed ID: 23791619
[TBL] [Abstract][Full Text] [Related]
30. Bronchoepithelial expression of CXCR1 and CXCR2 does not facilitate transepithelial migration of neutrophils.
Schulz C; Stoelcker B; Ruhland B; Jentsch N; Steege A
Respiration; 2012; 84(2):108-16. PubMed ID: 22076427
[TBL] [Abstract][Full Text] [Related]
31. Walking a tightrope: targeting neutrophils to treat chronic obstructive pulmonary disease.
Aaron SD
Am J Respir Crit Care Med; 2015 May; 191(9):971-2. PubMed ID: 25932758
[No Abstract] [Full Text] [Related]
32. Evaluation of Circulating Markers of Neutrophil Extracellular Trap (NET) Formation as Risk Factors for Diabetic Retinopathy in a Case-Control Association Study.
Park JH; Kim JE; Gu JY; Yoo HJ; Park SH; Kim YI; Nam-Goong IS; Kim ES; Kim HK
Exp Clin Endocrinol Diabetes; 2016 Oct; 124(9):557-561. PubMed ID: 27420129
[No Abstract] [Full Text] [Related]
33. Neutrophil Extracellular Traps in Atherosclerosis and Atherothrombosis.
Döring Y; Soehnlein O; Weber C
Circ Res; 2017 Feb; 120(4):736-743. PubMed ID: 28209798
[TBL] [Abstract][Full Text] [Related]
34. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects.
Holz O; Khalilieh S; Ludwig-Sengpiel A; Watz H; Stryszak P; Soni P; Tsai M; Sadeh J; Magnussen H
Eur Respir J; 2010 Mar; 35(3):564-70. PubMed ID: 19643947
[TBL] [Abstract][Full Text] [Related]
35. Expanding role of CXCR2 and therapeutic potential of CXCR2 antagonists in inflammatory diseases and cancers.
Xie Y; Kuang W; Wang D; Yuan K; Yang P
Eur J Med Chem; 2023 Mar; 250():115175. PubMed ID: 36780833
[TBL] [Abstract][Full Text] [Related]
36. Mediators and molecular pathways involved in the regulation of neutrophil extracellular trap formation mediated by activated platelets.
Carestia A; Kaufman T; Rivadeneyra L; Landoni VI; Pozner RG; Negrotto S; D'Atri LP; Gómez RM; Schattner M
J Leukoc Biol; 2016 Jan; 99(1):153-62. PubMed ID: 26320263
[TBL] [Abstract][Full Text] [Related]
37. Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis.
Moss RB; Mistry SJ; Konstan MW; Pilewski JM; Kerem E; Tal-Singer R; Lazaar AL;
J Cyst Fibros; 2013 May; 12(3):241-8. PubMed ID: 22995323
[TBL] [Abstract][Full Text] [Related]
38. Targets of Neutrophil Influx and Weaponry: Therapeutic Opportunities for Chronic Obstructive Airway Disease.
Mårdh CK; Root J; Uddin M; Stenvall K; Malmgren A; Karabelas K; Thomas M
J Immunol Res; 2017; 2017():5273201. PubMed ID: 28596972
[TBL] [Abstract][Full Text] [Related]
39. Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment.
Parnham MJ; Culić O; Eraković V; Munić V; Popović-Grle S; Barisić K; Bosnar M; Brajsa K; Cepelak I; Cuzić S; Glojnarić I; Manojlović Z; Novak-Mircetić R; Oresković K; Pavicić-Beljak V; Radosević S; Sucić M
Eur J Pharmacol; 2005 Jul; 517(1-2):132-43. PubMed ID: 15964564
[TBL] [Abstract][Full Text] [Related]
40. Discovery of Novel CXCR2 Inhibitors Using Ligand-Based Pharmacophore Models.
Ha H; Debnath B; Odde S; Bensman T; Ho H; Beringer PM; Neamati N
J Chem Inf Model; 2015 Aug; 55(8):1720-38. PubMed ID: 26153616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
